// App-Quantinova.ai

TCT-448 : BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II) 4 Year Clinical Results

Researchers

Presenter

  • ton slagboom

Principal Investigators

  • Michael Haude

  • Thierry Lefevre

  • Johannes Bilger

  • Salim Hayek

  • Karl Stangl

  • Franz-Josef Neumann

  • Rafaelruiz Salmeron

  • Manel Sabate

  • Gert Richardt

  • Bela Merkely

  • Javier Goicolea

Medical Centers

  • Klinikum Nurnberg Nord, Nurnberg, Germany

  • Institut Hospitalier Jacques Cartier, Massy, France

  • Unknown, Berlin, Germany

  • Swiss Cardiovascular Center Bern, Bern, Switzerland

  • Polyclinique les Fleurs, ollioules, France

  • Lukaskrankenhaus GmbH Neuss, Neuss, Germany

  • HOSPITAL V.MACARENA, POZUELO DE ALARCON(MADRID), Spain

  • MedStar Heart institute, Washington, District of Columbia, United States

  • Budapest, Hungary

  • Unknown, Madrid, Spain

  • Universitaets-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany

  • VUmc, Amsterdam, Netherlands

  • IRB Barcelona, Barcelona, Spain

  • Heart Center, Segeberger Kliniken, Bad Segeberg, Germany

Locations

  • Netherlands

  • Germany

  • Spain

  • Switzerland

  • United States

  • France

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Coronary artery lesions

  • Venous thrombosis

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved